NewsSTAT
Heuristic editor, no API keyVerdict: RoutineSTAT+: Merck suffers a setback in Europe over its new Keytruda formulation
In a setback for Merck, a Dutch court ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries.
Score████░░░░░░4.4
VerdictCompetent work. Briefs at most.
Summary from the source
In a setback for Merck, a Dutch court ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ██░░░ 2 | 15% | Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt). |
| Magnitude | ██░░░ 2 | 20% | Solid incremental gain on a meaningful problem. |
| Evidence | ███░░ 3 | 20% | Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data. |
| Novelty | ██░░░ 2 | 10% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 10% | Some room to improve with obvious engineering. |
| Stakes | ██░░░ 2 | 25% | Benefits a professional community (practitioners, clinicians, engineers). |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: verification (error bars).
How the score was computed
Score████░░░░░░4.4
- Merit
- 4.4 / 10
- Adjusted merit
- 4.4 / 10
- Attention
- 0%
- Freshness
- 0%